Please ensure Javascript is enabled for purposes of website accessibility

Should You Retire With Covidien?

By Jordan DiPietro – Updated Apr 6, 2017 at 8:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Does this company have the traits of a good retirement stock?

Being able to retire rich, or at least comfortable, is the goal of almost any investor. However, that's much easier said than done. In a recent Wells Fargo survey, respondents between the ages of 50 and 59 said that they had, on average, about $29,000 saved up. With pensions pretty much gone, and Social Security targeted for cuts in the future, it's hard to count on anyone but yourself. But $29,000 isn't going to cut it for most people, so you have to get involved in the stock market to grow that nest egg. Getting in the game is the easy part; choosing the right stocks is the hard part.

Making prudent decisions
Generally speaking, I look for four traits in a retirement stock:

  1. Valuation: Investors of all ages want to make sure they're not overpaying for a stock, but this matters even more in retirement. Retirees don't have the long time horizon that younger investors have, so it's essential to make sure you don't overpay in the short term.
  2. Dividends: Most retirees need a combination of both growth and income, as they'll be depending more and more on their portfolios to help with everyday expenses. Companies that pay dividends not only offer immediate income, but they've also proved to outperform non-paying dividend companies over long periods of time.
  3. Growth: Investors love dividends, but we all want to see our stocks rise over time. Growth can be as big a part of your portfolio as a steady dividend. It's important to note that you don't need a high-flying stock that's going to shoot to the moon; a company that can grow and outperform the market is hard enough to find, so steady growth is highly covetable.
  4. Low volatility: Retirees want to invest in great growth stocks just as much as anyone else does, but they also want to be able to rest well knowing that their portfolio won't be taking them on a roller-coaster ride. Most retirees would rather own a sturdy company that lets them sleep at night than a company that whips up and down with the gyrations of the market.

Although some companies are definitely more geared toward retirees, which companies you choose to invest in will be dictated largely by what you already have in your portfolio. Small, mid-, and large caps can all play a role in your investing strategy, so I've chosen to evaluate all varieties of stocks in this regular series.

So how does Covidien stack up?
To check out the valuation of Covidien (NYSE: COV), we don't want to look at only its P/E ratio of 15.7. That may seem expensive, but really we don't know without looking at the ratio in historical context. Over the past five years, Covidien's average P/E ratio has been 17.5, which is more than the current ratio. Investors may be paying less than they have in the past, so you might want to take advantage and scoop up some shares on the cheap.

Covidien's dividend is 1.50%. That might not seem like a whole lot right now, but it has room to grow, so I wouldn't discount its importance. Getting a dividend at all shows a company's dedication to its shareholders, and that's significant.

Next, we want to ensure that Covidien's stock has the ability to climb over the next five, 10, or 20 years. A company that's growing its net income has the best possible chance to see its share price rise over time. Of course, we can't predict the future, but we can look back to get an idea of how the company has performed in the past to try to ensure future earnings growth. Over the past two years, Covidien has grown its net income by 16.3% annually. Fortunately, it's been able to grow its earnings over the past two years, and that's pretty significant considering all of the recent market turmoil. Of course, this doesn't mean growth will continue, but it's a great sign that the company can prosper in the face of difficulty.

One of the best gauges of volatility is beta, which measures the impact that the movement of the stock market will have on a particular stock. For instance, a beta of 1.0 signifies that Covidien will move in tandem with the market, a beta of 2.0 means that the stock will move up twice as much as the market, and so on. In this case, Covidien has a beta of 0.82, which is pretty low. Generally speaking, I like to see a beta below 1.2 for retirees, and Covidien fits the bill.

Let's look at the competition
We've taken a look at Covidien, and maybe you think it's passed all the tests, or maybe you just don't feel comfortable with the results. In any event, it's beneficial to see how a company stacks up in its industry, because it's just as important to understand a company's competitors as it is to understand that particular company. Here are Covidien's stats when compared with three of its closest competitors.

Company

Current P/E

Dividend Yield

2-Year Net Income CAGR

1-Year Beta

Covidien  15.9 1.4% 16.3% 0.8
Becton, Dickinson (NYSE: BDX) 14.9 1.9% 7.5% 0.6
Johnson & Johnson  (NYSE: JNJ) 14.8 3.5% (2.3%) 0.6
AngioDynamics (Nasdaq: ANGO) 27.1 N/A 29.8% 0.7

Source: Capital IQ, a division of Standard & Poor's.

Each company has traits to like and traits that leave something to be desired. Either way, it's beneficial to look at the industry picture and not just Covidien in isolation.

Of course, I can't decide for you whether this is the best stock for retirement, but it has passed all four of our tests, which is pretty darned impressive. Not too many stocks can fit the bill for all four traits, so I would encourage you to dig deeper if you're already interested in health-care stocks.

Interested in adding any of the companies above to your watchlist? Get the latest commentary and analysis.

Jordan DiPietro owns no shares of the companies mentioned here. The Fool owns shares of Wells Fargo andJohnson & Johnson. Motley Fool newsletter services have recommended buying shares of Covidien, Becton, and Johnson & Johnson and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Covidien plc Stock Quote
Covidien plc
COV.DL
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.70 (-0.61%) $-1.02
Becton, Dickinson and Company Stock Quote
Becton, Dickinson and Company
BDX
$231.64 (-0.97%) $-2.28
AngioDynamics, Inc. Stock Quote
AngioDynamics, Inc.
ANGO
$20.04 (0.80%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.